115 related articles for article (PubMed ID: 30809967)
1. Study on Drug-Drug Interactions Between Chiglitazar, a Novel PPAR Pan-Agonist, and Metformin Hydrochloride in Healthy Subjects.
Yi L; Zhang H; Zhang JW; You XM; Ning ZQ; Yu J; Qian LF; Miao LY
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):934-941. PubMed ID: 30809967
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study.
Xu HR; Zhang JW; Chen WL; Ning ZQ; Li XN
Clin Drug Investig; 2019 Jun; 39(6):553-563. PubMed ID: 31037611
[TBL] [Abstract][Full Text] [Related]
3. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator-Activated Receptor Pan-Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes.
Li X; Yu J; Wu M; Li Q; Liu J; Zhang H; Zhu X; Li C; Zhang J; Ning Z; Ding Y
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):789-796. PubMed ID: 33345463
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers.
Moon SJ; Kim SY; Lim CH; Jang HB; Kim MG; Jeon JY
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):408-419. PubMed ID: 27739231
[TBL] [Abstract][Full Text] [Related]
6. Comparative Bioavailability of Metformin Hydrochloride Oral Solution Versus Metformin Hydrochloride Tablets in Fasting Mexican Healthy Volunteers.
Garza-Ocañas L; González-Canudas J; Tamez-de la O E; Badillo-Castañeda C; Gómez-Meza MV; Romero-Antonio Y; Molina-Pérez A; Amador-Hernández AG
Adv Ther; 2019 Feb; 36(2):407-415. PubMed ID: 30565181
[TBL] [Abstract][Full Text] [Related]
7. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects.
Cho HY; Yoon H; Lim YC; Lee YB
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):770-9. PubMed ID: 19954716
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
10. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects.
Rhee SJ; Choi Y; Lee S; Oh J; Kim SJ; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2016; 10():2525-34. PubMed ID: 27570447
[TBL] [Abstract][Full Text] [Related]
12. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects.
Rocha JF; Vaz-da-Silva M; Almeida L; Falcão A; Nunes T; Santos AT; Martins F; Fontes-Ribeiro C; Macedo T; Soares-da-Silva P
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):255-61. PubMed ID: 19356391
[TBL] [Abstract][Full Text] [Related]
13. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
Smolders EJ; Colbers A; de Kanter CTMM; Velthoven-Graafland K; Wolberink LT; van Ewijk-Beneken Kolmer N; Drenth JPH; Aarnoutse RE; Tack CJ; Burger DM
Br J Clin Pharmacol; 2017 Oct; 83(10):2225-2234. PubMed ID: 28474741
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin.
Choi HK; Oh M; Kim EJ; Song GS; Ghim JL; Shon JH; Kim HS; Shin JG
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):147-53. PubMed ID: 25546164
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects.
Ding Y; Zhang H; Li C; Zheng W; Wang M; Li Y; Sun H; Wu M
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):725-731. PubMed ID: 33899649
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
Lee SW; Park SI; Lee S; Chung JY; Yu KS
Int J Clin Pharmacol Ther; 2019 Feb; 57(2):117-124. PubMed ID: 30574864
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects.
Huh KY; Kim E; Lee H; Jeon I; Suh H; Lee J; Lee Y; Yu KS; Lee S
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):207-213. PubMed ID: 32579298
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
20. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]